The extracellular environment contains a wide assortment of proteoglycans that interact in a complex manner with proteins and peptides resulting in a variety of important biological consequences. Heparan sulfate is one of the most important proteoglycans in the extracellular matrix. Heparin, a related glycosaminoglycan, has been much more extensively studied for the ability to interact with proteins because heparin is a readily available anticoagulant that is a commercial drug. Heparan sulfate and heparin have many similar structural features, and both interact with many extracellular matrix proteins. Experiments over the past 5 years have begun to provide an understanding of the structural requirements for these interactions to occur. Heparin and heparan sulfate binding proteins with specific sites rich in basic residues, often contained in secondary structural domains that bind acidic oligosaccharides with high specificity and affinity. Recent studies suggest that specific sequences also exist within glycosaminoglycans that have high specificity and affinity for binding protein partners. This application is based upon these new observations, and proposes to produce and evaluate """"""""designer"""""""" glycosaminoglycans with increased specificity and affinity for binding to proteins. The first grant period allowed this laboratory to develop a much clearer understanding of the structural requirements for glycosaminoglycans and proteins to interact. In this renewal period, the laboratory will evaluate the hypotheses that 1) glycosaminoglycans from various tissues differ in binding affinities and specificities for proteins and peptides and 2) designer glycosaminoglycans can be produced that have enhanced affinity and specificity for bind partners. The primary aims are to: 1) examine tissue specific differences in heparan sulfate; 2) design and construct protein binding sites in glycosaminoglycans; and 3) perform fundamental structure-activity relationship studies to determine in much more detail, requirements for glycosaminoglycans and proteins to interact by studying thermodynamics, kinetics, precise contact points and other important factors that influence these interactions. The principal glycosaminoglycan target will be heparan sulfate, prepared from selected tissues of normal and knockout mice and modified with 3-O-sulfotransferase isoforms to construct structurally unique binding sites. The secondary aims are to develop high-through-put methods for screening glycosaminoglycan-protein interactions; expand the library of structurally defined oligosaccharides; and evaluate new biophysical methods for studying glycosaminoglycan-protein interactions.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
7R01HL052622-09
Application #
6886467
Study Section
Pathobiochemistry Study Section (PBC)
Program Officer
Marino, Pamela
Project Start
1996-02-01
Project End
2006-03-31
Budget Start
2004-04-01
Budget End
2006-03-31
Support Year
9
Fiscal Year
2003
Total Cost
$257,250
Indirect Cost
Name
Rensselaer Polytechnic Institute
Department
Type
DUNS #
002430742
City
Troy
State
NY
Country
United States
Zip Code
12180
Guerrini, Marco; Beccati, Daniela; Shriver, Zachary et al. (2008) Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26:669-75
Copeland, Ronald; Balasubramaniam, Arun; Tiwari, Vaibhav et al. (2008) Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1. Biochemistry 47:5774-83
Garg, Hari G; Mrabat, Hicham; Yu, Lunyin et al. (2008) Significance of the 2-O-sulfo group of L-iduronic acid residues in heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells. Carbohydr Res 343:2406-10
Zhang, Zhenqing; McCallum, Scott A; Xie, Jin et al. (2008) Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc 130:12998-3007
Warda, Mohamad; Zhang, Fuming; Radwan, Moustafa et al. (2008) Is human placenta proteoglycan remodeling involved in pre-eclampsia? Glycoconj J 25:441-50
Murugesan, Saravanababu; Xie, Jin; Linhardt, Robert J (2008) Immobilization of heparin: approaches and applications. Curr Top Med Chem 8:80-100
Bhattacharyya, Sumit; Gill, Ravinder; Chen, Mei Ling et al. (2008) Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells. J Biol Chem 283:10550-8
Zhang, Zhenqing; Weiwer, Michel; Li, Boyangzi et al. (2008) Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem 51:5498-501
Ma, Qing; Tobu, Mahmut; Schultz, Christopher et al. (2007) Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thromb Res 119:653-61
Ma, Qing; Cornelli, Umberto; Hanin, Israel et al. (2007) Heparin oligosaccharides as potential therapeutic agents in senile dementia. Curr Pharm Des 13:1607-16

Showing the most recent 10 out of 103 publications